 This is a randomized, double-blind, placebo-controlled biomarker study in renal transplant recipients with actinic damage and a history of basal cell carcinomas andor cutaneous squamous cell carcinomas. There will be two arms to the study: 1 daily oral UAB30 for 28 days; and 2 daily oral placebo for 28 days. The total duration of the study is anticipated to be 5 years. The hypothesis being tested is that a significantly greater percentage of subjects randomized to oral UAB30 over a period of 28 days will achieve 30 reduction in biomarkers of proliferation and 30 increase in apoptosis biomarkers than those who receive placebo. Cyclin D1 will serve as the primary biomarker. 